These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8844888)

  • 1. A phase I study of a hypoxic cell sensitizer KU-2285 in combination with conventional radiotherapy.
    Shibamoto Y; Takahashi M; Abe M
    Radiother Oncol; 1996 Jul; 40(1):55-8. PubMed ID: 8844888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I/II study of a hypoxic cell radiosensitizer KU-2285 in combination with intraoperative radiotherapy.
    Shibamoto Y; Ohshio G; Hosotani R; Nishimura Y; Manabe T; Imamura M; Abe M
    Br J Cancer; 1997; 76(11):1474-9. PubMed ID: 9400944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Final report of the phase I trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole) Radiation Therapy Oncology Group 83-03.
    Coleman CN; Wasserman TH; Urtasun RC; Halsey J; Noll L; Hancock S; Phillips TL
    Int J Radiat Oncol Biol Phys; 1990 Feb; 18(2):389-93. PubMed ID: 2154420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase Ia study of a hypoxic cell sensitizer doranidazole (PR-350) in combination with conventional radiotherapy.
    Nemoto K; Shibamoto Y; Ohmagari J; Baba Y; Ebe K; Ariga H; Takai Y; Ouchi A; Sasai K; Shinozaki M; Tsujitani M; Sakaguchi M; Yamada S; Sakamoto K
    Anticancer Drugs; 2001 Jan; 12(1):1-6. PubMed ID: 11272282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses.
    Dische S; Saunders MI; Lee ME; Adams GE; Flockhart IR
    Br J Cancer; 1977 May; 35(5):567-79. PubMed ID: 861146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A fluorinated 2-nitroimidazole, KU-2285, as a new hypoxic cell radiosensitizer.
    Sasai K; Nishimoto S; Shimokawa K; Hisanaga Y; Kitakabu Y; Shibamoto Y; Zhou L; Wang J; Takahashi M; Kagiya T
    Int J Radiat Oncol Biol Phys; 1991 Jun; 20(6):1249-54. PubMed ID: 1828462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo radiosensitizing activity of a new fluorinated hypoxic cell radiosensitizer, KU-2285, in combination with radiation dose fractionation.
    Sasai K; Fushiki M; Yukawa Y; Suyama S; Iwai H; Shibamoto Y; Nishimoto S; Takahashi M; Abe M
    Int J Radiat Oncol Biol Phys; 1991 Oct; 21(5):1231-4. PubMed ID: 1938521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optical isomers of a new 2-nitroimidazole nucleoside analog (PR-350 series): radiosensitization efficiency and toxicity.
    Oya N; Shibamoto Y; Sasai K; Shibata T; Murata R; Takagi T; Iwai H; Suzuki T; Abe M
    Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):119-27. PubMed ID: 7642409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of the combination of two hypoxic cell radiosensitizers, Ro 03-8799 and SR-2508: toxicity and pharmacokinetics.
    Newman HF; Bleehen NM; Workman P
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1113-6. PubMed ID: 2943709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Final report of the phase I trial of continuous infusion etanidazole (SR 2508): a Radiation Therapy Oncology Group study.
    Coleman CN; Noll L; Riese N; Buswell L; Howes AE; Loeffler JS; Alexander E; Wen P; Harris JR; Kramer RA
    Int J Radiat Oncol Biol Phys; 1992; 22(3):577-80. PubMed ID: 1531217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The multi-dose clinical tolerance and pharmacokinetics of the combined radiosensitizers, Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
    Newman HF; Ward R; Workman P; Bleehen NM
    Int J Radiat Oncol Biol Phys; 1988 Nov; 15(5):1073-83. PubMed ID: 2972667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged metronidazole administration with protracted radiotherapy: a pilot study on response of advanced tumours.
    Karim AB
    Br J Cancer Suppl; 1978 Jun; 3():299-301. PubMed ID: 277249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multiple dose study of the combined radiosensitizers Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
    Bleehen NM; Newman HF; Maughan TS; Workman P
    Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1093-6. PubMed ID: 2539346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiosensitization efficacy of KU-2285, RP-170 and etanidazole at low radiation doses: assessment by in vitro cytokinesis-block micronucleus assay.
    Shibamoto Y; Streffer C; Sasai K; Oya N; Abe M
    Int J Radiat Biol; 1992 Apr; 61(4):473-8. PubMed ID: 1349329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial clinical experience with the radiosensitizing nitroimidazole Ro 07-0582.
    Jentzsch K; Kärcher KH; Kogelnik HD; Maida E; Mamoli B; Wessely P; Zaunbauer F; Nitsche V
    Strahlentherapie; 1977 Dec; 153(12):825-31. PubMed ID: 601838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Radiosensitizer: hypoxic cell radiosensitizer].
    Mori T
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1399-404. PubMed ID: 2525001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Present status of radiation sensitizers--hypoxic cell radiosensitizer].
    Murayama C; Mori T
    Gan To Kagaku Ryoho; 1989 Jun; 16(6):2135-41. PubMed ID: 2660744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiosensitization by a new potent nucleoside analog: 1-(1',3',4'-trihydroxy-2'-butoxy)methyl-2-nitroimidazole(RP-343).
    Murayama C; Suzuki A; Sato C; Tanabe Y; Shoji T; Miyata Y; Nishio A; Suzuki T; Sakaguchi M; Mori T
    Int J Radiat Oncol Biol Phys; 1993 Jun; 26(3):433-43. PubMed ID: 8514541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of fluorinated nitroazoles as hypoxic cell radiosensitizers.
    Shibamoto Y; Nishimoto S; Shimokawa K; Hisanaga Y; Zhou L; Wang J; Sasai K; Takahashi M; Abe M; Kagiya T
    Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1045-8. PubMed ID: 2703384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radical irradiation and misonidazole in the treatment of T2 grade III and T3 bladder cancer.
    Abratt RP; Sealy R; Tucker RD; Williams MA; Barnes DR; Johnson MB; Green JA; Cridland JS
    Int J Radiat Oncol Biol Phys; 1983 May; 9(5):629-32. PubMed ID: 6853264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.